Home >> Tag Archives: EKF Diagnostics—

Tag Archives: EKF Diagnostics—

PCT assay for Beckman AU analyzers, 1/18

January 2018—EKF Diagnostics announced that its Stanbio Chemistry Procalcitonin LiquiColor assay has been FDA cleared and validated for use on Beckman Coulter AU480, 680, and 5800 clinical chemistry analyzers. EKF confirms the immediate availability of a user defined application for running this 10-minute test for bacterial infection and sepsis on these ­analyzers.

Read More »

EKF PCT assay cleared for Beckman AU analyzers

Nov. 29, 2017—EKF Diagnostics announced that its Stanbio Chemistry Procalcitonin LiquiColor assay has been FDA cleared and validated for use on Beckman AU 480, 680, and 5800 clinical chemistry analyzers. EKF confirms the immediate availability of a user defined application for running this 10-minute test for bacterial infection and sepsis on these analyzers. EKF’s PCT test is designed to be ...

Read More »

POC connectivity solution for HbA1c analyzers, 3/17

March 2017—EKF Diagnostics previewed a point-of-care connectivity solution for its range of HbA1c analyzers at Medica 2016 in November in Düsseldorf, Germany. Its connectivity package for Quo-Test and Quo-Lab HbA1c analyzers enable secure, bi-directional communication between the POC analyzers and a multitude of central data management systems.

Read More »

Benchtop clinical chemistry analyzer, 9/15

EKF Diagnostics launched its Altair 240 clinical chemistry analyzerEKF Diagnostics launched its Altair 240 clinical chemistry analyzer, a benchtop platform that is EKF’s first fully integrated chemistry system for the global market. The fully automated system has LIS bidirectional connectivity, and double arm functionality yields up to 480 tests per hour.

Read More »

Diabetic biomarker test, 5/15

May 2015—EKF Diagnostics has introduced the Stanbio Chemistry Glycated Serum Protein LiquiColor test, a diabetic biomarker test that provides a two- to three-week indicator of average blood glucose, closing the information gap between daily blood glucose testing and the two- to three-month HbA1c reading. GSP serves as an accurate intermediate marker of glycemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan, and hemodialysis.

Read More »

Hemoglobin analyzer, plasma centrifuge, 9/14

September 2014—EKF Diagnostics highlighted its expanding product portfolio at its subsidiary’s booth, Stanbio Laboratory. DiaSpect Tm, which previewed at the meeting, is a palm-sized hemoglobin measurement system that gives laboratory-quality performance for anemia screening. Delivering results in one to two seconds, this analyzer is CE marked and currently undergoing FDA approval.

Read More »

EKF, Joslin Diabetes Center collaboration, 2/15

February 2014—EKF Diagnostics has entered a multiyear collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of tumor necrosis factor receptor 1 and 2 biomarkers. EKF will access certain clinical and research expertise at Joslin under the center’s corporate liaison program to further develop its TNFR biomarker test.

Read More »

EKF Molecular, MGH announce collaboration, 12/14

December 2014—EKF Diagnostics announced it has entered a two-year research collaboration with Massachusetts General Hospital to develop PointMan assays that can detect treatable cancer mutations in blood samples. MGH will use PointMan DNA for the detection of genetic variation in circulating tumor cells isolated from a patient’s blood using MGH’s CTC-Chip instrument.

Read More »
X